Open-label study of craving in smokers with schizophrenia using nicotine nasal spray compared to nicotine patch

Jill M. Williams, Kunal K. Gandhi, Maria Katsamanis Karavidas, Marc L. Steinberg, Shou En Lu, Jonathan Foulds

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Rationale: Nicotine nasal spray (NNS) may be better for relieving acute cigarette cravings than other nicotine replacement and it may help smokers with schizophrenia because of its rapid onset of action. Objectives: We tested whether NNS was more effective than a nicotine patch (NP; 21 mg) in reducing cue-induced craving during a 3-day abstinence. Methods: Twenty-five smokers with schizophrenia or schizoaffective disorder (SA) were randomized to open-label NNS or NP treatment after baseline measures of craving were assessed. NNS users were instructed to dose at a minimum of 1/hour and up to a maximum of 40/day. Averages from a 4-item visual analogue scale (need, urge, want to smoke, crave a cigarette) measured craving. Results: Five subjects who smoked (4 NP, 1 NNS) were excluded, leaving 21 (11 NP, 10 NNS) for analyses. No differences were detected between groups on baseline craving. On day 3, NNS users reported significantly less craving in response to smoking cues compared to NP users (mean craving scores: NNS, 7.0; NP, 20.3; p =.014). A repeated measure ANCOVA demonstrated significantly reduced craving in the NNS group compared to the NP group from baseline to day 3 (F = 5.09; p =.037). NNS users took an average of 20 doses/day, and NNS was rated as being as easy to use as NP. Conclusions: The potential utility of NNS in smokers with schizophrenia supports the need for placebo-controlled studies. 2008 by The Haworth Press. All rights reserved.

Original languageEnglish (US)
Pages (from-to)355-376
Number of pages22
JournalJournal of Dual Diagnosis
Volume4
Issue number4
DOIs
StatePublished - Oct 16 2008

Fingerprint

Tobacco Use Cessation Products
Schizophrenia
Tobacco Products
Craving
Cues
Visual Analog Scale
Nicotine
Smoke
Psychotic Disorders

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health

Cite this

Williams, Jill M. ; Gandhi, Kunal K. ; Karavidas, Maria Katsamanis ; Steinberg, Marc L. ; Lu, Shou En ; Foulds, Jonathan. / Open-label study of craving in smokers with schizophrenia using nicotine nasal spray compared to nicotine patch. In: Journal of Dual Diagnosis. 2008 ; Vol. 4, No. 4. pp. 355-376.
@article{f80522566969443f8dda043387f8013d,
title = "Open-label study of craving in smokers with schizophrenia using nicotine nasal spray compared to nicotine patch",
abstract = "Rationale: Nicotine nasal spray (NNS) may be better for relieving acute cigarette cravings than other nicotine replacement and it may help smokers with schizophrenia because of its rapid onset of action. Objectives: We tested whether NNS was more effective than a nicotine patch (NP; 21 mg) in reducing cue-induced craving during a 3-day abstinence. Methods: Twenty-five smokers with schizophrenia or schizoaffective disorder (SA) were randomized to open-label NNS or NP treatment after baseline measures of craving were assessed. NNS users were instructed to dose at a minimum of 1/hour and up to a maximum of 40/day. Averages from a 4-item visual analogue scale (need, urge, want to smoke, crave a cigarette) measured craving. Results: Five subjects who smoked (4 NP, 1 NNS) were excluded, leaving 21 (11 NP, 10 NNS) for analyses. No differences were detected between groups on baseline craving. On day 3, NNS users reported significantly less craving in response to smoking cues compared to NP users (mean craving scores: NNS, 7.0; NP, 20.3; p =.014). A repeated measure ANCOVA demonstrated significantly reduced craving in the NNS group compared to the NP group from baseline to day 3 (F = 5.09; p =.037). NNS users took an average of 20 doses/day, and NNS was rated as being as easy to use as NP. Conclusions: The potential utility of NNS in smokers with schizophrenia supports the need for placebo-controlled studies. 2008 by The Haworth Press. All rights reserved.",
author = "Williams, {Jill M.} and Gandhi, {Kunal K.} and Karavidas, {Maria Katsamanis} and Steinberg, {Marc L.} and Lu, {Shou En} and Jonathan Foulds",
year = "2008",
month = "10",
day = "16",
doi = "10.1080/15504260802085919",
language = "English (US)",
volume = "4",
pages = "355--376",
journal = "Journal of Dual Diagnosis",
issn = "1550-4263",
publisher = "Routledge",
number = "4",

}

Open-label study of craving in smokers with schizophrenia using nicotine nasal spray compared to nicotine patch. / Williams, Jill M.; Gandhi, Kunal K.; Karavidas, Maria Katsamanis; Steinberg, Marc L.; Lu, Shou En; Foulds, Jonathan.

In: Journal of Dual Diagnosis, Vol. 4, No. 4, 16.10.2008, p. 355-376.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Open-label study of craving in smokers with schizophrenia using nicotine nasal spray compared to nicotine patch

AU - Williams, Jill M.

AU - Gandhi, Kunal K.

AU - Karavidas, Maria Katsamanis

AU - Steinberg, Marc L.

AU - Lu, Shou En

AU - Foulds, Jonathan

PY - 2008/10/16

Y1 - 2008/10/16

N2 - Rationale: Nicotine nasal spray (NNS) may be better for relieving acute cigarette cravings than other nicotine replacement and it may help smokers with schizophrenia because of its rapid onset of action. Objectives: We tested whether NNS was more effective than a nicotine patch (NP; 21 mg) in reducing cue-induced craving during a 3-day abstinence. Methods: Twenty-five smokers with schizophrenia or schizoaffective disorder (SA) were randomized to open-label NNS or NP treatment after baseline measures of craving were assessed. NNS users were instructed to dose at a minimum of 1/hour and up to a maximum of 40/day. Averages from a 4-item visual analogue scale (need, urge, want to smoke, crave a cigarette) measured craving. Results: Five subjects who smoked (4 NP, 1 NNS) were excluded, leaving 21 (11 NP, 10 NNS) for analyses. No differences were detected between groups on baseline craving. On day 3, NNS users reported significantly less craving in response to smoking cues compared to NP users (mean craving scores: NNS, 7.0; NP, 20.3; p =.014). A repeated measure ANCOVA demonstrated significantly reduced craving in the NNS group compared to the NP group from baseline to day 3 (F = 5.09; p =.037). NNS users took an average of 20 doses/day, and NNS was rated as being as easy to use as NP. Conclusions: The potential utility of NNS in smokers with schizophrenia supports the need for placebo-controlled studies. 2008 by The Haworth Press. All rights reserved.

AB - Rationale: Nicotine nasal spray (NNS) may be better for relieving acute cigarette cravings than other nicotine replacement and it may help smokers with schizophrenia because of its rapid onset of action. Objectives: We tested whether NNS was more effective than a nicotine patch (NP; 21 mg) in reducing cue-induced craving during a 3-day abstinence. Methods: Twenty-five smokers with schizophrenia or schizoaffective disorder (SA) were randomized to open-label NNS or NP treatment after baseline measures of craving were assessed. NNS users were instructed to dose at a minimum of 1/hour and up to a maximum of 40/day. Averages from a 4-item visual analogue scale (need, urge, want to smoke, crave a cigarette) measured craving. Results: Five subjects who smoked (4 NP, 1 NNS) were excluded, leaving 21 (11 NP, 10 NNS) for analyses. No differences were detected between groups on baseline craving. On day 3, NNS users reported significantly less craving in response to smoking cues compared to NP users (mean craving scores: NNS, 7.0; NP, 20.3; p =.014). A repeated measure ANCOVA demonstrated significantly reduced craving in the NNS group compared to the NP group from baseline to day 3 (F = 5.09; p =.037). NNS users took an average of 20 doses/day, and NNS was rated as being as easy to use as NP. Conclusions: The potential utility of NNS in smokers with schizophrenia supports the need for placebo-controlled studies. 2008 by The Haworth Press. All rights reserved.

UR - http://www.scopus.com/inward/record.url?scp=71049165621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71049165621&partnerID=8YFLogxK

U2 - 10.1080/15504260802085919

DO - 10.1080/15504260802085919

M3 - Article

C2 - 19763279

AN - SCOPUS:71049165621

VL - 4

SP - 355

EP - 376

JO - Journal of Dual Diagnosis

JF - Journal of Dual Diagnosis

SN - 1550-4263

IS - 4

ER -